


Lithuania

This country fact sheet accompanies the EHC heat map and gives you further information on the country's progress over the various EHC surveys.

Here, you will see how the FVIII international units provision has evolved and compares to other countries. You will also find the same parameters as in the heat map.



Change since previous	ssurvey: ▲ Improvement ▼ Decline	2009		2012		2015		2018
International units	Factor VIII	1.95	A	3.37	A	4.33	A	6.47
per capita	Factor IX	0.24	A	0.62	A	0.82	A	1.28
Organisation	Comprehensive Care Centres (CCC's)	Yes	•	No	A	Yes		Yes
of care	Haemophilia Treatment Centres	Yes		Yes		Yes		Yes
	National Haemophilia Council or Co-ordinating Group	Yes		Yes	▼	No		No
	Number of groups in decision-making on haemophilia care	3	▼	2	A	3		3
	Number of groups choosing haemophilia treatment products	3	▼	1	A	3		3
	National Tender for procurement of factor concentrates	Yes		Yes		Yes	•	No
Treatment	Home Treatment	Yes		Yes		Yes		Yes
regimens	% of people with haemophilia using home treatment	76-100%		76-100%		76-100%		76-100%
	Treatment delivered to the patient's home	No		Unknown		No		Some
	Prophylaxis treatment availability	Some		Some		Some	A	Yes
	Children currently on prophy (%)	1-25%	A	76-100%		76-100%		76-100%
	Adults currently on prophy (%)	0		0		1-25%	A	51-75%
	Access to ITI (% of people with inhibitors)	1-25%		1-25%		1-25%		1-25%
Access to	Emergency medicine and acute surgery	Yes		Yes		Yes		Yes
specialist services	Paediatrics	Yes		Yes		Yes		Yes
	Infectious disease specialists (especially HIV)	Yes		Yes	▼	Sometimes	A	Yes
	Hepatology	Yes		Yes	•	Sometimes	A	Yes
	Rheumatology	Yes		Yes	•	Sometimes	A	Yes
	Orthopaedics	Yes		Yes		Yes		Yes
	Physiotherapy	Yes		Yes		Yes		Yes
	Dentistry	Yes		Yes		Yes		Yes
	Obstetrics and Gynaecology	Sometimes	A	Yes		Yes		Yes
	Genetics	Sometimes	A	Yes		Yes		Yes
	Social and psychological support	Yes		Yes	•	Sometimes	A	Yes
	Pain management	Yes		Yes	•	Sometimes	A	Yes
	General surgery	Yes		Yes	•	Sometimes	A	Yes
	Urology	Yes		Yes	•	Sometimes	A	Yes
Share of Expected	Haemophilia A	46%	A	49%	A	50%	A	53%
Bleeding Disorder	Haemophilia B	131%	▼	22%	A	25%	A	28%
Prevalence	von Willebrand Disease	1%	A	10%	A	10%	A	11%
Haemophilia	Pasma-derived factor concentrate	Always		Always		Always		Always
replacement	Recombinant factor concentrate	Rarely	A	Always		Always		Always
therapy	Plasma	Never		Never		Never		Never
	Cryoprecipitate	Never		Never		Never		Never
VWD replacement	Plasma-derived factor concentrate	Always	▼	Rarely	A	Always		Always
therapy	DDAVP	Always	_	Rarely		Rarely		Rarely
	Plasma	Rarely	A	Never		,		Never
	Cryoprecipitate	Never		Never				Never